and thiazolidinediones (TZD) in the ACCORD-MIND cohort. Methods Participants (55–80
years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c)> 7.5%(> 58 mmol/mol), and a
high risk of cardiovascular events were randomly assigned to receive intensive control
targeting HbA1c to< 6.0%(42 mmol/mol) or a standard strategy targeting HbA1c to 7.0%–
7.9%(53–63 mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at …